Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Liabilities and Shareholders Equity (2016 - 2025)

Voyager Therapeutics' Liabilities and Shareholders Equity history spans 11 years, with the latest figure at $252.3 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 35.81% year-over-year to $252.3 million; the TTM value through Dec 2025 reached $1.2 billion, down 29.51%, while the annual FY2025 figure was $252.3 million, 35.81% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $252.3 million at Voyager Therapeutics, down from $288.3 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $469.6 million in Q1 2024 and bottomed at $159.4 million in Q4 2022.
  • The 5-year median for Liabilities and Shareholders Equity is $291.5 million (2023), against an average of $290.9 million.
  • The largest annual shift saw Liabilities and Shareholders Equity skyrocketed 120.44% in 2023 before it tumbled 35.81% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $193.9 million in 2021, then decreased by 17.8% to $159.4 million in 2022, then surged by 120.44% to $351.3 million in 2023, then increased by 11.89% to $393.0 million in 2024, then crashed by 35.81% to $252.3 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Liabilities and Shareholders Equity are $252.3 million (Q4 2025), $288.3 million (Q3 2025), and $322.1 million (Q2 2025).